JP2006508056A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006508056A5 JP2006508056A5 JP2004532947A JP2004532947A JP2006508056A5 JP 2006508056 A5 JP2006508056 A5 JP 2006508056A5 JP 2004532947 A JP2004532947 A JP 2004532947A JP 2004532947 A JP2004532947 A JP 2004532947A JP 2006508056 A5 JP2006508056 A5 JP 2006508056A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- antibody
- ligand
- group
- antagonist
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 23
- 102000002627 4-1BB Ligand Human genes 0.000 claims 8
- 108010082808 4-1BB Ligand Proteins 0.000 claims 8
- 239000005557 antagonist Substances 0.000 claims 6
- 230000003042 antagnostic effect Effects 0.000 claims 4
- 229940045799 anthracyclines and related substance Drugs 0.000 claims 4
- 208000031229 Cardiomyopathies Diseases 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 102000004127 Cytokines Human genes 0.000 claims 2
- 108090000695 Cytokines Proteins 0.000 claims 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 2
- 208000009525 Myocarditis Diseases 0.000 claims 2
- 206010003119 arrhythmia Diseases 0.000 claims 2
- 230000006793 arrhythmia Effects 0.000 claims 2
- 208000010125 myocardial infarction Diseases 0.000 claims 2
- 208000008494 pericarditis Diseases 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims 1
- 239000005541 ACE inhibitor Substances 0.000 claims 1
- 206010048610 Cardiotoxicity Diseases 0.000 claims 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 claims 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 claims 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 101000783356 Naja sputatrix Cytotoxin Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 229940035676 analgesics Drugs 0.000 claims 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims 1
- 239000000730 antalgic agent Substances 0.000 claims 1
- 230000003110 anti-inflammatory effect Effects 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 230000036772 blood pressure Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 231100000259 cardiotoxicity Toxicity 0.000 claims 1
- 239000002340 cardiotoxin Substances 0.000 claims 1
- 231100000677 cardiotoxin Toxicity 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 229960000975 daunorubicin Drugs 0.000 claims 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims 1
- 229960004679 doxorubicin Drugs 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229960001904 epirubicin Drugs 0.000 claims 1
- 208000019622 heart disease Diseases 0.000 claims 1
- 210000005003 heart tissue Anatomy 0.000 claims 1
- 229960000908 idarubicin Drugs 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 239000007943 implant Substances 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 229960001156 mitoxantrone Drugs 0.000 claims 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 1
- 239000003614 peroxisome proliferator Substances 0.000 claims 1
- 230000002685 pulmonary effect Effects 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 239000012730 sustained-release form Substances 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40641802P | 2002-08-28 | 2002-08-28 | |
| US49445703P | 2003-08-12 | 2003-08-12 | |
| PCT/US2003/026354 WO2004019866A2 (en) | 2002-08-28 | 2003-08-21 | Compositions and methods for treating cardiovascular disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006508056A JP2006508056A (ja) | 2006-03-09 |
| JP2006508056A5 true JP2006508056A5 (enExample) | 2006-09-28 |
Family
ID=31981396
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004532947A Pending JP2006508056A (ja) | 2002-08-28 | 2003-08-21 | 心臓血管疾患を治療するための組成物および方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US20040136992A1 (enExample) |
| EP (1) | EP1545578A4 (enExample) |
| JP (1) | JP2006508056A (enExample) |
| AU (1) | AU2003259995B2 (enExample) |
| CA (1) | CA2496795C (enExample) |
| MX (1) | MXPA05002219A (enExample) |
| PL (1) | PL376536A1 (enExample) |
| WO (1) | WO2004019866A2 (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8377114B2 (en) | 1999-08-09 | 2013-02-19 | Cardiokinetix, Inc. | Sealing and filling ventricular partitioning devices to improve cardiac function |
| US10307147B2 (en) | 1999-08-09 | 2019-06-04 | Edwards Lifesciences Corporation | System for improving cardiac function by sealing a partitioning membrane within a ventricle |
| US8257428B2 (en) | 1999-08-09 | 2012-09-04 | Cardiokinetix, Inc. | System for improving cardiac function |
| US8529430B2 (en) | 2002-08-01 | 2013-09-10 | Cardiokinetix, Inc. | Therapeutic methods and devices following myocardial infarction |
| US8500795B2 (en) | 1999-08-09 | 2013-08-06 | Cardiokinetix, Inc. | Retrievable devices for improving cardiac function |
| US7674222B2 (en) | 1999-08-09 | 2010-03-09 | Cardiokinetix, Inc. | Cardiac device and methods of use thereof |
| US9694121B2 (en) | 1999-08-09 | 2017-07-04 | Cardiokinetix, Inc. | Systems and methods for improving cardiac function |
| US10064696B2 (en) | 2000-08-09 | 2018-09-04 | Edwards Lifesciences Corporation | Devices and methods for delivering an endocardial device |
| US9078660B2 (en) | 2000-08-09 | 2015-07-14 | Cardiokinetix, Inc. | Devices and methods for delivering an endocardial device |
| US9332993B2 (en) | 2004-08-05 | 2016-05-10 | Cardiokinetix, Inc. | Devices and methods for delivering an endocardial device |
| US9332992B2 (en) | 2004-08-05 | 2016-05-10 | Cardiokinetix, Inc. | Method for making a laminar ventricular partitioning device |
| US7291331B1 (en) * | 2002-09-11 | 2007-11-06 | La Jolla Institute For Allergy And Immunology | Methods of treating OX40 medicated recall immune responses |
| ATE459647T1 (de) * | 2003-04-15 | 2010-03-15 | Glaxosmithkline Llc | Humane il-18 substitutionsmutanten und deren konjugate |
| BRPI0411526A (pt) | 2003-06-18 | 2006-08-01 | Genelux Corp | vìrus de vaccinia e outros microrganismos recombinates modificados e usos dos mesmos |
| US7288638B2 (en) | 2003-10-10 | 2007-10-30 | Bristol-Myers Squibb Company | Fully human antibodies against human 4-1BB |
| GB0417487D0 (en) | 2004-08-05 | 2004-09-08 | Novartis Ag | Organic compound |
| WO2007038703A2 (en) * | 2005-09-28 | 2007-04-05 | Zymogenetics, Inc | Il-17a and il-17f antagonists and methods of using the same |
| TWI461436B (zh) | 2005-11-25 | 2014-11-21 | Kyowa Hakko Kirin Co Ltd | 人類ｃｄ１３４（ｏｘ４０）之人類單株抗體及其製造及使用方法 |
| EP1973949A2 (en) | 2005-12-16 | 2008-10-01 | Genentech, Inc. | Anti-ox40l antibodies and methods using same |
| WO2007130724A2 (en) | 2006-02-06 | 2007-11-15 | Northwind Ventures | Systems and methods for volume reduction |
| MX2009009194A (es) * | 2007-02-27 | 2009-10-08 | Genentech Inc | Anticuerpos ox40 antagonistas y su uso en el tratamiento de enfermedades inflamatorias y autoinmunes. |
| WO2008109379A1 (en) * | 2007-03-02 | 2008-09-12 | Mdrna, Inc. | Nucleic acid compounds for inhibiting il17a gene expression and uses thereof |
| PE20091174A1 (es) | 2007-12-27 | 2009-08-03 | Chugai Pharmaceutical Co Ltd | Formulacion liquida con contenido de alta concentracion de anticuerpo |
| JP5875986B2 (ja) | 2009-10-26 | 2016-03-02 | カーディオキネティックス・インコーポレイテッドＣａｒｄｉｏｋｉｎｅｔｉｘ， Ｉｎｃ． | 心室容積縮小 |
| EP3372617B1 (en) * | 2010-04-02 | 2024-07-24 | Amunix Pharmaceuticals, Inc. | Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same |
| US9284283B2 (en) | 2012-02-02 | 2016-03-15 | Ensemble Therapeutics Corporation | Macrocyclic compounds for modulating IL-17 |
| JP2016504050A (ja) * | 2013-01-17 | 2016-02-12 | モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | 細胞表現型の改変のためのシグナルセンサーポリヌクレオチド |
| EP3197397B1 (en) | 2014-09-28 | 2021-01-13 | Cardiokinetix, Inc. | Apparatuses for treating cardiac dysfunction |
| CN107949570A (zh) * | 2015-06-30 | 2018-04-20 | 勃林格殷格翰国际有限公司 | 多特异性结合蛋白 |
| EP3192805A1 (en) * | 2016-01-15 | 2017-07-19 | Humanitas Mirasole S.p.A. | Inhibitors of t cell activation or stimulation and uses thereof |
| DE102018107407A1 (de) | 2017-03-28 | 2018-10-04 | Edwards Lifesciences Corporation | Positionieren, einsetzen und zurückholen von implantierbaren vorrichtungen |
| CN111320691B (zh) * | 2018-12-17 | 2022-04-05 | 程联胜 | 一种抗人4-1bb单克隆抗体及其应用 |
| WO2021209050A1 (en) * | 2020-04-17 | 2021-10-21 | Biocytogen Jiangsu Co., Ltd. | Genetically modified non-human animal with human or chimeric tnfsf9 and/or 4-1bb |
| CN113730388B (zh) * | 2021-10-22 | 2024-06-21 | 浙江大学 | 辛酸钠在制备改善心肺复苏效果以及心肺复苏后多器官功能障碍的药物中的应用 |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5457A (en) | 1848-02-22 | Behch-vise | ||
| US4737462A (en) | 1982-10-19 | 1988-04-12 | Cetus Corporation | Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β |
| US4518584A (en) | 1983-04-15 | 1985-05-21 | Cetus Corporation | Human recombinant interleukin-2 muteins |
| DE3586772T2 (de) | 1984-07-24 | 1993-03-04 | Coselco Mimotopes Pty Ltd | Verfahren zur bestimmung von mimotopen. |
| US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
| US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
| US5071972A (en) | 1986-01-31 | 1991-12-10 | Genetics Institute, Inc. | DNA sequences encoding novel thrombolytic proteins |
| NL8720442A (nl) | 1986-08-18 | 1989-04-03 | Clinical Technologies Ass | Afgeefsystemen voor farmacologische agentia. |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5011912A (en) | 1986-12-19 | 1991-04-30 | Immunex Corporation | Hybridoma and monoclonal antibody for use in an immunoaffinity purification system |
| EP0315456B1 (en) | 1987-11-05 | 1994-06-01 | Hybritech Incorporated | Polysaccharide-modified immunoglobulins having reduced immunogenic potential or improved pharmacokinetics |
| US6303121B1 (en) * | 1992-07-30 | 2001-10-16 | Advanced Research And Technology | Method of using human receptor protein 4-1BB |
| US6362325B1 (en) * | 1988-11-07 | 2002-03-26 | Advanced Research And Technology Institute, Inc. | Murine 4-1BB gene |
| US20060002904A9 (en) * | 1988-11-07 | 2006-01-05 | Kwon Byoung S | Receptor and related products and methods |
| US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| CA2089661C (en) | 1990-08-29 | 2007-04-03 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5716805A (en) | 1991-10-25 | 1998-02-10 | Immunex Corporation | Methods of preparing soluble, oligomeric proteins |
| US5262522A (en) | 1991-11-22 | 1993-11-16 | Immunex Corporation | Receptor for oncostatin M and leukemia inhibitory factor |
| DK0615451T3 (da) | 1992-05-26 | 2006-04-24 | Immunex Corp | Hidtil ukendt cytokin der binder til CD30 |
| US5792451A (en) | 1994-03-02 | 1998-08-11 | Emisphere Technologies, Inc. | Oral drug delivery compositions and methods |
| NZ258697A (en) | 1992-11-13 | 1996-03-26 | Immunex Corp | Elk-l polypeptide, coding sequence and vector therefor |
| US7211259B1 (en) * | 1993-05-07 | 2007-05-01 | Immunex Corporation | 4-1BB polypeptides and DNA encoding 4-1BB polypeptides |
| WO1994026290A1 (en) | 1993-05-07 | 1994-11-24 | Immunex Corporation | Cytokine designated 4-1bb ligand and human receptor that binds thereto |
| US6274711B1 (en) * | 1993-06-14 | 2001-08-14 | Inserm, Institut National De La Sante Et De La Recherche Medicale | Purified mammalian CTLA-8 antigens and related reagents |
| US5457035A (en) | 1993-07-23 | 1995-10-10 | Immunex Corporation | Cytokine which is a ligand for OX40 |
| US5470952A (en) | 1993-10-20 | 1995-11-28 | Regeneron Pharmaceuticals, Inc. | CNTF and IL-6 antagonists |
| US5821332A (en) | 1993-11-03 | 1998-10-13 | The Board Of Trustees Of The Leland Stanford Junior University | Receptor on the surface of activated CD4+ T-cells: ACT-4 |
| US6242566B1 (en) | 1994-02-10 | 2001-06-05 | Board Of Trustees Of The Leland Stanford Junior University | Ligand (ACT-4-L) to a receptor on the surface of activated CD4+ T-cells |
| US6407059B1 (en) | 1994-06-08 | 2002-06-18 | Peptor Limited | Conformationally constrained backbone cyclized peptide analogs |
| US6309853B1 (en) | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
| US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
| US6169073B1 (en) | 1995-02-16 | 2001-01-02 | Bayer Corporation | Peptides and peptidomimetics with structural similarity to human p53 that activate p53 function |
| US5877155A (en) | 1995-03-17 | 1999-03-02 | The Research Foundation Of State University Of New York | Mimotopes and anti-mimotopes of human platelet glycoprotein Ib/IX |
| MX9707021A (es) | 1995-03-23 | 1997-11-29 | Immunex Corp | Receptor de il-7. |
| ATE226641T1 (de) * | 1995-04-08 | 2002-11-15 | Lg Chemical Ltd | Humaner 4-1bb spezifischer humaner antikörper und diesen produzierende zellinie |
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| US6127977A (en) | 1996-11-08 | 2000-10-03 | Cohen; Nathan | Microstrip patch antenna with fractal structure |
| US5776731A (en) | 1996-02-21 | 1998-07-07 | Immunex Corporation | DNA encoding type-I interleukin-I receptor-like protein designated 2F1 |
| AU728657B2 (en) | 1996-03-18 | 2001-01-18 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| US6060283A (en) | 1996-06-27 | 2000-05-09 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Genomic DNA encoding human interleukin-18 (IL-18, interferon-γ inducing factor) |
| TW515843B (en) | 1996-07-25 | 2003-01-01 | Hayashibara Biochem Lab | Process for producing an active polypeptide inducing interferon-γ production |
| ES2326347T3 (es) * | 1996-11-27 | 2009-10-07 | Immunex Corporation | Metodo para regular la produccion de oxido nitrico. |
| US6087116A (en) | 1997-03-12 | 2000-07-11 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Interleukin-18 (IL-18) receptor polypeptides and their uses |
| IL121860A0 (en) | 1997-08-14 | 1998-02-22 | Yeda Res & Dev | Interleukin-18 binding proteins their preparation and use |
| WO1999037772A1 (en) | 1998-01-23 | 1999-07-29 | Immunex Corporation | Il-18 receptors |
| PL343427A1 (en) * | 1998-07-15 | 2001-08-13 | Merckle Gmbh | Utilization of cd137 in order to promote the proliferation of peripheral monocytes |
| AU6425699A (en) | 1998-10-16 | 2000-05-08 | Cornell Research Foundation Inc. | Methods of inhibiting platelet activation and recruitment |
| US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| KR20000034847A (ko) * | 1998-11-17 | 2000-06-26 | 성재갑 | 인간 4-1비비 분자에 대한 인간화 항체 및 이를 포함하는 약학조성물 |
| WO2002058717A2 (en) * | 2000-10-18 | 2002-08-01 | Immunex Corporation | Methods for treating rheumatoid arthritis using il-17 antagonists |
| US20040028687A1 (en) * | 2002-01-15 | 2004-02-12 | Waelti Ernst Rudolf | Methods and compositions for the targeted delivery of therapeutic substances to specific cells and tissues |
| WO2004055513A2 (en) | 2002-12-16 | 2004-07-01 | Herbert Schwarz | Use of cd137 antagonists for the treatment of tumors |
-
2003
- 2003-08-21 AU AU2003259995A patent/AU2003259995B2/en not_active Expired
- 2003-08-21 PL PL376536A patent/PL376536A1/pl not_active Application Discontinuation
- 2003-08-21 JP JP2004532947A patent/JP2006508056A/ja active Pending
- 2003-08-21 CA CA2496795A patent/CA2496795C/en not_active Expired - Lifetime
- 2003-08-21 US US10/646,308 patent/US20040136992A1/en not_active Abandoned
- 2003-08-21 MX MXPA05002219A patent/MXPA05002219A/es unknown
- 2003-08-21 WO PCT/US2003/026354 patent/WO2004019866A2/en not_active Ceased
- 2003-08-21 EP EP03791726A patent/EP1545578A4/en not_active Withdrawn
-
2012
- 2012-06-26 US US13/533,727 patent/US8529894B2/en not_active Expired - Fee Related
-
2013
- 2013-08-07 US US13/961,691 patent/US20130323258A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006508056A5 (enExample) | ||
| WO2004019866B1 (en) | Compositions and methods for treating cardiovascular disease | |
| ES2734523T3 (es) | Combinaciones sinérgicas que comprenden un inhibidor de renina para enfermedades cardiovasculares | |
| JP2013506696A5 (enExample) | ||
| TWI428131B (zh) | 使用升壓素拮抗劑以減少因接受蒽環類抗生素化療劑治療造成之心血管毒性和／或改善存活率之方法 | |
| TWI455723B (zh) | 納曲酮及安非他酮於治療超重或肥胖病患之用途 | |
| JP2002532392A5 (enExample) | ||
| Sever | Candesartan cilexetil: a new, long-acting, effective angiotensin II type 1 receptor blocker. | |
| JP2013501802A5 (enExample) | ||
| Khadka et al. | Macitentan: An important addition to the treatment of pulmonary arterial hypertension | |
| TW201127422A (en) | Transdermally absorbed preparation of anti-dementia drug | |
| JP6768646B2 (ja) | Ｐｇｉ２受容体に関連した状態の治療法 | |
| WO2007098387A3 (en) | Antihypertensive therapy | |
| US20210121418A1 (en) | Treatment of proteinuria | |
| JP2009256379A (ja) | 心不全を治療又は予防するための、シロブラジン又はその医薬として許容される塩の使用 | |
| JP6878596B2 (ja) | Ｆｘｒアゴニストの組合せ | |
| JP2008540364A5 (enExample) | ||
| ES2400446T3 (es) | Tratamiento con glucocorticoides de liberación retardada de una enfermedad reumática | |
| TW201143817A (en) | Transdermally absorbed preparation of anti-dementia drug | |
| JPS6393716A (ja) | 遅延型経皮活性剤投与デバイス | |
| JP2007520564A5 (enExample) | ||
| JP2007532646A5 (enExample) | ||
| JP2021526554A (ja) | 肛門直腸疾患の治療のための局所的なアムロジピン塩 | |
| Spinar et al. | Anti-hypertensive strategies in patients with MEtabolic parameters, DIabetes mellitus and/or NephropAthy (the MEDINA study) | |
| CA2632931A1 (en) | Use of cicletanine and other furopyridines for treatment of hypertension |